Phase II Peprostat study 'a major milestone' says Ergomed's Andrew Mackie

Published on 20th Mar 2017

Ergomed's (LON:ERGO) chief business officer Andrew Mackie and Ben Nichols, CEO of subsidiary Haemostatix spoke to Proactive's Andrew Scott about the start of recruiting for a phase IIb proof-of-concept study on Peprostat - which will be used to treat a surgical complication called intraoperative bleeding.

Pharma & Biotech
Add to favorites
Share with:

Related Videos

Latest

Pharma & Biotech
Concepta secures two additional myLotus distribution agreements in China

Concepta secures two additional myLotus distribution agreements in China

Published on 16th Oct 2017
Tech
Keywords' Andrew Day shows off shiny new AIM award

Keywords' Andrew Day shows off shiny new AIM award

Published on 16th Oct 2017
Media & Publishing
London Finance Show: Iran and Spain weighing on markets

London Finance Show: Iran and Spain weighing on markets

Published on 16th Oct 2017

Recommended videos

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082.
You can contact us here.

Choose Proactive Region: